UK Community Advisory Board (UK-CAB)

UK-CAB 67: Friday 23 November 2018

Undetectable equals Untransmittable – What we know now: Friday 23 November 2018


Tea and refreshments

Welcome and introductions
UK-CAB updates and company pre-meeting

Company meeting: ViiV Healthcare


‘U=U – The Clinician’s Perspective’, Dr Laura Waters

Lunch – The Marquis Cornwallis

‘U=U – The Community Perspective’, Matthew Hodson

‘BHIVA U=U Initiative’, Jo Josh


‘HIV Glasgow 2018, PRISM Study, BHIVA ART Guidelines’, Roy Trevelion

Meeting close

Background reading and videos/webcasts

Dolutegravir _ 3TC – Gemini Studies

Cabotegravir + rilpivirine long acting inectable treatment

Cabotegravir injections for PrEP – especially the “tail”

Fostemsavir – drug resistant HIV drug

ViiV U=U video
The video was recently made by one of the main HIV pharmaceutical companies.

U=U is also part of an international campaign to raise awareness about this benefit of ART. Currently, more than 720 organisations have joined from over 90 countries.

Q&A on U=U
Questions and answers about U=U.

The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk
This article reviews key studies over the last twenty years that are the evidence for U=U.


Company Presentation by ViiV Healthcare UK (link)

‘U=U – The Clinician’s Perspective’ by Doctor Laura Waters (link)

‘U=U’ – The Community Perspective’ by Matthew Hodson. (link)

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research. For a list of companies that support the UK-CAB please see the “about us” page.